669 related articles for article (PubMed ID: 18076933)
1. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.
Israeli RS; Ryan CW; Jung LL
J Urol; 2008 Feb; 179(2):414-23. PubMed ID: 18076933
[TBL] [Abstract][Full Text] [Related]
2. Bone health in men receiving androgen deprivation therapy for prostate cancer.
Eastham JA
J Urol; 2007 Jan; 177(1):17-24. PubMed ID: 17161994
[TBL] [Abstract][Full Text] [Related]
3. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.
Ross RW; Small EJ
J Urol; 2002 May; 167(5):1952-6. PubMed ID: 11956415
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma.
Smith MR
Cancer; 2003 Feb; 97(3 Suppl):789-95. PubMed ID: 12548577
[TBL] [Abstract][Full Text] [Related]
5. Bone health in men with prostate cancer: diagnostic and therapeutic considerations.
Saad F; Perrotte P; Bénard F; McCormack M; Karakiewicz PI
Can J Urol; 2005 Jun; 12 Suppl 2():9-15. PubMed ID: 16018826
[TBL] [Abstract][Full Text] [Related]
6. Bone related events in high risk prostate cancer.
Srinivas S; Colocci N
J Urol; 2006 Dec; 176(6 Pt 2):S50-4. PubMed ID: 17084167
[TBL] [Abstract][Full Text] [Related]
7. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.
Smith MR
Oncology (Williston Park); 2004 May; 18(5 Suppl 3):21-5. PubMed ID: 15202584
[TBL] [Abstract][Full Text] [Related]
8. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
Smith MR; Eastham J; Gleason DM; Shasha D; Tchekmedyian S; Zinner N
J Urol; 2003 Jun; 169(6):2008-12. PubMed ID: 12771706
[TBL] [Abstract][Full Text] [Related]
9. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
Higano CS
Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
[TBL] [Abstract][Full Text] [Related]
10. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
Bhoopalam N; Campbell SC; Moritz T; Broderick WR; Iyer P; Arcenas AG; Van Veldhuizen PJ; Friedman N; Reda D; Warren S; Garewal H
J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
12. Progressive osteoporosis during androgen deprivation therapy for prostate cancer.
Daniell HW; Dunn SR; Ferguson DW; Lomas G; Niazi Z; Stratte PT
J Urol; 2000 Jan; 163(1):181-6. PubMed ID: 10604342
[TBL] [Abstract][Full Text] [Related]
13. Influence of insolation on osteoporosis progression in androgen deprived nonmetastatic prostate cancer patients.
Spanjol J; Maricić A; Valencić M; Oguić R; Krpina K; Protić A; Ivancić A; Bobinac M; Fuckar D; Vojniković B
Coll Antropol; 2008 Oct; 32 Suppl 2():79-81. PubMed ID: 19138011
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
[TBL] [Abstract][Full Text] [Related]
15. Osteoporosis during androgen deprivation therapy for prostate cancer.
Smith MR
Urology; 2002 Sep; 60(3 Suppl 1):79-85; discussion 86. PubMed ID: 12231056
[TBL] [Abstract][Full Text] [Related]
16. Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates.
Polascik TJ
Prostate Cancer Prostatic Dis; 2008; 11(1):13-9. PubMed ID: 17923854
[TBL] [Abstract][Full Text] [Related]
17. Cancer treatment-induced bone loss in breast and prostate cancer.
Saad F; Adachi JD; Brown JP; Canning LA; Gelmon KA; Josse RG; Pritchard KI
J Clin Oncol; 2008 Nov; 26(33):5465-76. PubMed ID: 18955443
[TBL] [Abstract][Full Text] [Related]
18. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?
Higano CS
Nat Clin Pract Urol; 2008 Jan; 5(1):24-34. PubMed ID: 18185511
[TBL] [Abstract][Full Text] [Related]
19. Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.
Morabito N; Gaudio A; Lasco A; Catalano A; Atteritano M; Trifiletti A; Anastasi G; Melloni D; Frisina N
J Bone Miner Res; 2004 Nov; 19(11):1766-70. PubMed ID: 15476575
[TBL] [Abstract][Full Text] [Related]
20. Oral bisphosphonate prevents bone loss in androgen deprivation therapy for nonmetastatic prostate cancer.
Kawahara T; Kobayashi T; Nishizawa K; Kobori G; Mitsumori K; Ogura K
Hinyokika Kiyo; 2008 Apr; 54(4):261-6. PubMed ID: 18516917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
